NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX), a biotechnology company in its late-clinical stage, is set to participate in the Jefferies Global Healthcare Conference. This event is scheduled for June 5, 2024, at 5:00 PM EDT in New York, NY. Bart Van Rhijn, the CFO of Nanobiotix, will be leading a fireside chat that will be webcast live on the company's website. The webcast will also be available for replay post-event.
- NANOBIOTIX's participation in a major healthcare conference could increase visibility and investor interest.
- The fireside chat led by the CFO may provide valuable insights into the company's financial health and strategy.
- The availability of the webcast replay ensures broader accessibility to the content presented.
- The press release lacks specific updates on clinical trial progress or financial performance, which may leave investors wanting more substantial news.
- No new partnerships, collaborations, or funding announcements are included, which could be seen as a missed opportunity for business development.
PARIS and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Please see below for details of the event.
Jefferies Global Healthcare Conference
Date: Wednesday, June 5, 2024
Time: 5:00 PM EDT / 11:00 PM CEST
Location: New York, NY
Presenter: Bart Van Rhijn, chief financial officer of Nanobiotix
Webcast link: click here
The fireside chat will be webcast live from the events page of the Investors section of the Company’s website. Replay of the webcast will be available following the event.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Disclaimer
This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 24, 2024 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2023 universal registration document filed with the AMF on April 24, 2024, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC’s website at www.sec.gov. The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.
Contacts
| Nanobiotix | |
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com |
| Media Relations | |
| FR – Ulysse Communication Laurent Wormser + 33 (0)6 13 12 04 04 lwormser@ulysse-communication.com | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com |
Attachment
FAQ
What is the date and time of the NANOBIOTIX presentation at the Jefferies Global Healthcare Conference?
Who will be presenting for NANOBIOTIX at the Jefferies Global Healthcare Conference?
How can I watch the NANOBIOTIX fireside chat at the Jefferies Global Healthcare Conference?
Will the NANOBIOTIX webcast from the Jefferies Global Healthcare Conference be available for replay?
